STAT6 degrader - Nurix/Sanofi
Latest Information Update: 07 May 2024
At a glance
- Originator Nurix
- Developer Nurix; Sanofi
- Class Anti-inflammatories; Small molecules
- Mechanism of Action STAT6 transcription factor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 09 Apr 2024 Preclinical trials in Inflammation in USA (unspecified route)
- 09 Apr 2024 Pharmacodynamics data from preclinical studies in inflammation released by Nurix
- 09 Apr 2024 Nurix plans to submit an IND application for the lead candidate and initiate a phase I trial for Inflammation by April 2025